Biodexa Pharmaceuticals Appoints Experienced Group Financial Controller Fiona Sharp as New CFO and Director
BDRX is trading near its 52-week low of $2.22 (8.1% above the low).
Summary
Biodexa Pharmaceuticals Plc has appointed Fiona Sharp, previously the Group Financial Controller, as its new Chief Financial Officer and a member of the Board of Directors, effective January 5, 2026. This move allows CEO Stephen Stamp to focus solely on his chief executive duties.
Key Events · Executive and Board Changes · BDRX
-
New Chief Financial Officer Appointed
Fiona Sharp has been appointed as Chief Financial Officer, Corporate Secretary, and a member of the Board of Directors, effective January 5, 2026.
-
CEO Focus Enhanced
Stephen Stamp relinquished his CFO and Corporate Secretary roles but remains Chief Executive Officer, allowing him to concentrate on strategic leadership.
-
Experienced Financial Leader
Ms. Sharp previously served as the company's Group Financial Controller since December 2019 and brings significant financial leadership experience from prior roles.
Analysis · BDRX · Life Sciences
The appointment of Fiona Sharp as Chief Financial Officer and Director is a positive development for Biodexa Pharmaceuticals, particularly given its micro-cap status. Ms. Sharp's internal promotion from Group Financial Controller, combined with her extensive financial leadership experience, suggests a seamless transition and a strengthening of the company's financial management. This change also allows Stephen Stamp to dedicate his full attention to the CEO role, which can enhance strategic focus and operational efficiency. For a small company, a well-defined executive structure with experienced leadership in key financial roles is crucial for investor confidence and long-term stability.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.22 to $92.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.